A Biotech Wall Around China Would Come at a Cost
Bloomberg opinion argues that US lawmakers pushing biotech companies to divest from China risk undermining American pharmaceutical innovation. Severing ties with China's fast-growing drug discovery ecosystem could cede competitive ground to Asian rivals in the race for new medicines. The piece warns that protectionist biotech policy may ultimately prove self-defeating for US interests.
The Atomic take
The BIOSECURE Act's push to cut ties with Chinese contract manufacturers like WuXi would force US drugmakers to rebuild supply chains that currently underpin a large share of early-stage discovery work, raising costs and slowing pipelines at a moment when speed defines competitive advantage in longevity therapeutics. Watch whether Congress attaches firm divestment deadlines to the next defense or appropriations bill, and how quickly biotechs can stand up alternative partners in India, South Korea, or domestically without ceding ground on the next generation of drugs.
Read the full story at Bloomberg →Know where humanity is headed.
Five forces. One brief. Free, every Monday morning.
Get The Atomic Five